Literature DB >> 23152494

High-density lipoprotein function, dysfunction, and reverse cholesterol transport.

Edward A Fisher1, Jonathan E Feig, Bernd Hewing, Stanley L Hazen, Jonathan D Smith.   

Abstract

Although high high-density lipoprotein (HDL)-cholesterol levels are associated with decreased cardiovascular risk in epidemiological studies, recent genetic and pharmacological findings have raised doubts about the beneficial effects of HDL. Raising HDL levels in animal models by infusion or overexpression of apolipoprotein A-I has shown clear vascular improvements, such as delayed atherosclerotic lesion progression and accelerated lesion regression, along with increased reverse cholesterol transport. Inflammation and other factors, such as myeloperoxidase-mediated oxidation, can impair HDL production and HDL function, with regard to its reverse cholesterol transport, antioxidant, and anti-inflammatory activities. Thus, tests of HDL function, which have not yet been developed as routine diagnostic assays, may prove useful and be a better predictor of cardiovascular risk than HDL-cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152494      PMCID: PMC3501261          DOI: 10.1161/ATVBAHA.112.300133

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  75 in total

1.  PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties.

Authors:  M Amine Bouhlel; Bruno Derudas; Elena Rigamonti; Rébecca Dièvart; John Brozek; Stéphan Haulon; Christophe Zawadzki; Brigitte Jude; Gérard Torpier; Nikolaus Marx; Bart Staels; Giulia Chinetti-Gbaguidi
Journal:  Cell Metab       Date:  2007-08       Impact factor: 27.287

2.  Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis.

Authors:  Katey J Rayner; Frederick J Sheedy; Christine C Esau; Farah N Hussain; Ryan E Temel; Saj Parathath; Janine M van Gils; Alistair J Rayner; Aaron N Chang; Yajaira Suarez; Carlos Fernandez-Hernando; Edward A Fisher; Kathryn J Moore
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

3.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

4.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.

Authors:  B J Van Lenten; S Y Hama; F C de Beer; D M Stafforini; T M McIntyre; S M Prescott; B N La Du; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

5.  Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages.

Authors:  Lemin Zheng; Megan Settle; Gregory Brubaker; Dave Schmitt; Stanley L Hazen; Jonathan D Smith; Michael Kinter
Journal:  J Biol Chem       Date:  2004-10-21       Impact factor: 5.157

6.  Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography.

Authors:  Scott M Gordon; Jingyuan Deng; L Jason Lu; W Sean Davidson
Journal:  J Proteome Res       Date:  2010-10-01       Impact factor: 4.466

7.  Non enzymatic glycation of apolipoprotein A-I. Effects on its self-association and lipid binding properties.

Authors:  C Calvo; C Talussot; G Ponsin; F Berthézène
Journal:  Biochem Biophys Res Commun       Date:  1988-06-30       Impact factor: 3.575

8.  Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I.

Authors:  Baohai Shao; Giorgio Cavigiolio; Nathan Brot; Michael N Oda; Jay W Heinecke
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

9.  Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle.

Authors:  Arundhati Undurti; Ying Huang; Joseph A Lupica; Jonathan D Smith; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

10.  Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides.

Authors:  Katey J Rayner; Christine C Esau; Farah N Hussain; Allison L McDaniel; Stephanie M Marshall; Janine M van Gils; Tathagat D Ray; Frederick J Sheedy; Leigh Goedeke; Xueqing Liu; Oleg G Khatsenko; Vivek Kaimal; Cynthia J Lees; Carlos Fernandez-Hernando; Edward A Fisher; Ryan E Temel; Kathryn J Moore
Journal:  Nature       Date:  2011-10-19       Impact factor: 49.962

View more
  132 in total

1.  HDL-apolipoprotein A-I exchange is independently associated with cholesterol efflux capacity.

Authors:  Mark S Borja; Kit F Ng; Angela Irwin; Jaekyoung Hong; Xing Wu; Daniel Isquith; Xue-Qiao Zhao; Bryan Prazen; Virginia Gildengorin; Michael N Oda; Tomáš Vaisar
Journal:  J Lipid Res       Date:  2015-08-07       Impact factor: 5.922

Review 2.  How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?

Authors:  Francine K Welty
Journal:  Curr Cardiol Rep       Date:  2013-09       Impact factor: 2.931

Review 3.  Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.

Authors:  David E Cohen; Edward A Fisher
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

4.  Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors.

Authors:  Jixin Zhong; Andrei Maiseyeu; Sanjay Rajagopalan
Journal:  Clin Lipidol       Date:  2015

5.  Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice.

Authors:  Bernd Hewing; Saj Parathath; Tessa Barrett; Wing Ki Kellie Chung; Yaritzy M Astudillo; Tadateru Hamada; Bhama Ramkhelawon; Thomas C Tallant; Mohamed Shaif S Yusufishaq; Joseph A Didonato; Ying Huang; Jennifer Buffa; Stela Z Berisha; Jonathan D Smith; Stanley L Hazen; Edward A Fisher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-01-09       Impact factor: 8.311

Review 6.  Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.

Authors:  Alan Chait; Ira Goldberg
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

7.  HDL from apoA1 transgenic mice expressing the 4WF isoform is resistant to oxidative loss of function.

Authors:  Stela Z Berisha; Greg Brubaker; Takhar Kasumov; Kimberly T Hung; Patricia M DiBello; Ying Huang; Ling Li; Belinda Willard; Katherine A Pollard; Laura E Nagy; Stanley L Hazen; Jonathan D Smith
Journal:  J Lipid Res       Date:  2015-01-05       Impact factor: 5.922

8.  AIBP protects against metabolic abnormalities and atherosclerosis.

Authors:  Dina A Schneider; Soo-Ho Choi; Colin Agatisa-Boyle; Laurence Zhu; Jungsu Kim; Jennifer Pattison; Dorothy D Sears; Philip L S M Gordts; Longhou Fang; Yury I Miller
Journal:  J Lipid Res       Date:  2018-03-20       Impact factor: 5.922

9.  Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.

Authors:  Yu Kataoka; Jordan Andrews; MyNgan Duong; Tracy Nguyen; Nisha Schwarz; Jessica Fendler; Rishi Puri; Julie Butters; Constance Keyserling; John F Paolini; Jean-Louis Dasseux; Stephen J Nicholls
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

10.  Site-specific 5-hydroxytryptophan incorporation into apolipoprotein A-I impairs cholesterol efflux activity and high-density lipoprotein biogenesis.

Authors:  Maryam Zamanian-Daryoush; Valentin Gogonea; Anthony J DiDonato; Jennifer A Buffa; Ibrahim Choucair; Bruce S Levison; Randall A Hughes; Andrew D Ellington; Ying Huang; Xinmin S Li; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2020-02-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.